Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study

Trial Profile

Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2015

At a glance

  • Drugs IC 51 (Primary)
  • Indications Japanese encephalitis
  • Focus Pharmacodynamics
  • Sponsors Valneva
  • Most Recent Events

    • 04 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 05 Dec 2013 Planned end date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 17 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top